MBX Biosciences (MBX) - Final Profit

Corporate emblem and logo of mbxbio.com (MBX)

The current market value of MBX Biosciences Inc (MBX) displayed on the GURU.Markets chart is -0.10. The business operates within a biotech environment where the absence of sales and dependence on FDA verdicts drive development. Projects are focused on combating metabolic disorders. The firm's competitiveness is based on long-acting drug technology that reduces injection frequency for the treatment of hormonal pathologies.

MBX Biosciences (MBX): Net Profit from 09/14/2024 to 10/31/2026

Financial and market metric breakdowns for MBX Biosciences (MBX)

- market value and analyst target forecast:
Stock Price MBX Corp|MBX - Consensus Target
- market capitalization indicators:
Market Value MBX Corp|MBX - Total Company Value
- business book valuation details:
Accounting Value per Share MBX Biosciences|MBX - Book Capitalization|Market-to-Book Ratio mbxbio.com|MBX - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Capital MBX Biosciences Inc|MBX - Long-Term Debt to Capital|Short-Term Debt to Capital MBX Biosciences, Inc.|MBX - Company Aggregate Debts|Debt to Book Capitalization Ratio MBX Corp|MBX - Company Long-Term Debt|Short-Term Debt MBX Biosciences|Quick Liquidity mbxbio.com
- net income and valuation ratios data:
MBX - Net Profit
Fundamental valuation:MBX Corp, MBX
Flagship merchandise of MBX Biosciences

Profit represents the final stream of operating income minus all current expenses. This metric allows for an assessment of financial stability and the potential for building dividend capital. By analyzing the net income dynamics of a company, an investor can timely identify the risks of overpaying for an asset. For MBX Biosciences Inc (MBX), this indicator reflects the efficiency of monetizing PEP technologies in endocrinology. Profit growth will confirm the commercial success of developing long-acting peptide drugs.

Main competitors

Ascendis (ASND) - Net Profit|Net Income MDGL|CORT: Final Profit|Company Net Income Rhythm Pharmaceuticals, Inc. (RYTM)|Net Income Akero Therapeutics, Inc. AKRO|Net Profit MTSR (Metsera Corp)|MoonLake Corp (MLTX) - Company Net Income|CRNX: Net Income|newamsterdampharma.com - Profit After Payment of Taxes|SLNO: Net Profit|Amicus Therapeutics Inc (FOLD) - Net Profit|ETNB (89bio Corp) - Net Profit|Company Net Income AGIO|Company Net Income Structure Therapeutics (GPCR)|MDXG - Company Net Income|Company Net Income Rezolute RZLT|Lexicon Pharmaceuticals Inc - Company Net Income|Altimmune Corp - Net Profit|Net Financial Result Aardvark Pharma AARD|Sagimet Biosciences (SGMT) - Company Net Income|BIOA - Net Financial Result|Company Net Income Biomea Fusion|Net Income Quince (QNCX)|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Net Profit ATPC (Agape ATP)|Pluristem Therapeutics - Company Net Income|SYBX: Net Income|LPCN (Lipocine Inc) - Company Profit|MTNB (matinasbiopharma.com) - Net Income|Spruce Biosciences Inc. - Final Profit|GLTO (Galecto, Inc.) - Net Profit|Company Net Income CTCX|Net Profit LUMO|Net Financial Result Organovo Holdings|Company Net Income Radius Health RDUS